Pasithea Therapeutics KTTA Institutional Ownership

Pasithea Therapeutics Corp. (NASDAQ:KTTA) has 25 institutional investors with active 13F positions as of June 2026.

• Collectively, these holders controlled 52.3% of Pasithea Therapeutics's outstanding shares in June 2026, down from 52.7% in March 2026.
• They increased total shares held in KTTA by 56.62% quarter over quarter, and investors in Pasithea Therapeutics increased 127.27% from a year ago.
• Of these 25 funds, 16 grew their exposure to Pasithea Therapeutics, 4 cut back, and 5 maintained positions.
• Combined, these investors held 16.79Mn shares in KTTA for June 2026, up by 6.07Mn shares quarter on quarter, and up 16.53Mn shares year over year.
• Cable Car Capital, LP is the top holder of Pasithea Therapeutics as of June 30, 2026, with 3.0Mn shares representing 9.35% of outstanding stock.
• The most significant purchases of KTTA for the quarter ending June 2026 came from Jupiter Topco LLC (2.1Mn), Opaleye Management Inc. (2.05Mn), Cable Car Capital, LP (1.79Mn), Stonepine Capital Management, LLC (1.37Mn), AdvisorShares Investments LLC (600.04K).
• The largest sales of KTTA for the quarter ending June 2026 came from Vivo Capital, LLC (1.63Mn), Squadron Capital Management LLC (1.1Mn), RENAISSANCE TECHNOLOGIES LLC (27.8K), GEODE CAPITAL MANAGEMENT, LLC (20.13K).
• Business Quant data shows the 10 biggest positions in Pasithea Therapeutics as of June 2026 are held by Cable Car Capital, LP (3.0Mn), Stonepine Capital Management, LLC (2.2Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.1Mn), Jupiter Topco LLC (2.1Mn), Opaleye Management Inc. (2.05Mn), Ameriprise Financial Inc (1.86Mn), Squadron Capital Management LLC (1.0Mn), AdvisorShares Investments LLC (937.55K), Vivo Capital, LLC (465.47K), Persistent Asset Partners Ltd (290.56K).